Biologicals revolutionized the treatment of Rheumatoid Arthritis (RA). The targeted suppression of key inflammatory pathways involved in joint inflammation and destruction allows better disease control, which, however, comes at the price of an elevated infection risk due to relative immunosuppression. The disease-related infection risk and the infection risk associated with the use of TNF-α inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol), rituximab, abatacept and tocilizumab are discussed. Risk factors clinicians need to take into account when selecting the most appropriate biologic therapy for RA patients, as well as precautions and screening concerning a number of specific infections, such as tuberculosis, intracellular bacterial infections, reactivation of chronic viral infections and HIV are reviewed.
Keywords: Rheumatoid arthritis, infection, biologicals, targeted therapies, TNF inhibitors, adalimumab, etanercept, golimumab, ertolizumab pegol, rituximab, abatacept, tocilizumab, tuberculosis,, B-cell specific, CD 20 antigen, corticosteroid, comorbidities, disease-modifying antirheumatic drugs (DMARDs), prednisolone, Progressive multifocal leukoencephalopathy, interferon-release assays, tuberculin skin test, tuberculosis-specific interferon-gamma release
TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Thiol-Dependent Enzymes and Their Inhibitors: A Review
Current Medicinal Chemistry Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?
Current Rheumatology Reviews Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Role of Bone Marrow in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Small Molecule Inhibitors of Lck: The Search for Specificity within a Kinase Family
Mini-Reviews in Medicinal Chemistry Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Progress Towards the Identification of New Aggrecanase Inhibitors
Current Medicinal Chemistry Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Current Drug Safety Mixed Connective Tissue Disease, a Roundabout to Rheumatic Diseases?
Current Rheumatology Reviews Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Anti-CCP Antibody Detection Facilitates Early Diagnosis and Prognosis of Rheumatoid Arthritis
Current Rheumatology Reviews Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry